Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is one of the most promising stocks according to Wall Street analysts. On June 24, ...

CLOs have effectively become the backbone of the loan market, accounting for ~50–70% of the demand for new leveraged loan ...

Syndax now has two approved therapies, but the share price remains under pressure despite these milestones. See why SNDX ...

– PDUFA action date set for October 25, 2025 – – sNDA being reviewed under FDA’s RTOR program – – Revumenib has the potential to become the first and only menin inhibitor approved in ...

A comprehensive new study lays bare the deadly toll of austerity, inequality and profit-driven healthcare are consigning an ...

The decision by the Carnegie Mellon University administration to host President Trump for an “Energy” conference on July 15 ...

The sNDA is being reviewed under the FDA's Real-Time Oncology Review (RTOR) program, which allows for a more efficient review and close engagement between the sponsor and FDA.

There are rumours however that acutely aware of its electoral deficits, its unpopularity with the wider masses and its lack ...

The sNDA, if approved, would expand the indication for Revuforj to include patients with R/R AML who have an NPM1 mutation, the most common genetic alteration in AML.

If U.S. citizenship for Puerto Ricans is no longer secure, then neither is the colonial arrangement that produced it.